Genflow Biosciences plc (LON:GENF)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 10.34M +0.9% |
| Revenue (ttm) | 585.61K +82.7% |
| Net Income | -1.10M |
| EPS | -0.00 |
| Shares Out | 566.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,715 |
| Open | 1.767 |
| Previous Close | 1.825 |
| Day's Range | 1.757 - 1.825 |
| 52-Week Range | 1.211 - 3.120 |
| Beta | 2.27 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 29, 2026 |
About Genflow Biosciences
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunct... [Read more]
Financial Performance
In 2025, Genflow Biosciences's revenue was 585,607, an increase of 82.73% compared to the previous year's 320,471. Losses were -1.42 million, -10.69% less than in 2024.
Financial StatementsNews
Genflow Biosciences PLC Announces Corporate Update
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Presentation of Interim Results
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Genflow Biosciences PLC Announces Half-year Financial Report
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser
LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces ...
Genflow Biosciences PLC Announces Patent Update
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary
LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year ...
Genflow Biosciences PLC Announces Result of AGM
LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announc...
Genflow Biosciences PLC Announces Participation at BIO International Convention 2026
LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad B...
Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Notice of AGM
Notice of Annual General Meeting and Board Changes LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the ...
Genflow Biosciences PLC Announces Final Results
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Strategic Technology Collaboration
Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April 20...
Genflow Biosciences PLC Announces International Patent Publication
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / March 31, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March...
Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Result of GM
Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company fo...
Genflow Biosciences PLC Announces Receipt of First Tranche of Grant
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Notice of GM
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Genflow Biosciences PLC Announces Holding(s) in Company
LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK ...
Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities
LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGU...
Genflow Biosciences PLC Announces Directorate Change
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...